Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Adipotide and Liraglutide — mechanism, side effects, legal status, and pricing.
Adipotide (FTPP) is a chimeric peptidomimetic developed in the Arap/Pasqualini lab (originally at MD Anderson) that couples a 9-residue homing motif (CKGGRAKDC) — isolated by in vivo phage display as a ligand for prohibitin on white-adipose-tissue vasculature — to the D-amino-acid pro-apoptotic domain D(KLAKLAK)2. It is an experimental research compound, NOT FDA-approved for any indication. A clinical-development program in prostate-cancer-associated obesity reached early-phase testing and was ultimately discontinued.
Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014). It was the first GLP-1 analog approved for obesity and carries an FDA boxed warning for the risk of thyroid C-cell tumors. Pediatric indications include type 2 diabetes in patients ≥10 years (Victoza) and obesity in patients ≥12 years with BMI ≥95th percentile (Saxenda).
Adipotide
Liraglutide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Adipotide
Liraglutide
1 vendor lists this, but none clear the trust bar (score ≥70) yet.
Check Liraglutide prices →COA corpus from Disclosed Labs — independently tested batches only.
Adipotide
2
COAs
98.8%
Avg purity
2
Labs
Liraglutide
No COA data yet.
Submit testing data →Foundational proof-of-concept in obese mice (Kolonin et al., Nat Med 2004, PMID 15133506). A 4-week dosing study in spontaneously obese rhesus macaques showed substantial body-weight and fat-mass loss and improved insulin sensitivity but produced dose-dependent renal proximal-tubule toxicity (Barnhart et al., Sci Transl Med 2011, PMID 22072637). A small Phase 1 trial in obese prostate-cancer patients was initiated and later terminated; the program was permanently discontinued. No published human efficacy data. Grey-market human use is unstudied and carries documented nephrotoxicity risk.
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015; PMID 26132939) demonstrated ~8% body-weight loss at 3.0 mg daily over 56 weeks, and the SCALE Diabetes trial (Davies et al., JAMA 2015; PMID 26284720) showed 6.0% weight loss in adults with type 2 diabetes. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; PMID 27295427) demonstrated a 13% relative reduction in major adverse cardiovascular events in type 2 diabetes with established CVD or high CV risk. A pediatric Phase 3 trial (Kelly et al., NEJM 2020; PMID 32233338) supported Saxenda's FDA approval for adolescents ≥12 years with obesity. While less effective than newer GLP-1 agonists for weight loss, liraglutide has the longest track record and most extensive real-world safety data. The daily dosing requirement is its main disadvantage versus weekly semaglutide.
Adipotide and Liraglutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs